Brief: CTI Biopharma Says Phase 1 Trial Shows Encouraging Clinical Benefit And Promising Safety Profile Of Pacritinib
22/03/2021 18:20
March 22 (Reuters) - CTI Biopharma Corp CTIC.O :
* PHASE 1 TRIAL DEMONSTRATES ENCOURAGING CLINICAL BENEFIT
AND
PROMISING SAFETY PROFILE OF PACRITINIB FOR THE PREVENTION OF
GRAFT-VERSUS-HOST DISEASE PUBLISHED IN CLINICAL CANCER RESEARCH
* CTI BIOPHARMA CORP - PHASE 2 INVESTIGATOR-SPONSORED
CLINICAL
TRIAL UNDERWAY TO FURTHER EVALUATE CLINICAL BENEFIT
Source text for Eikon: urn:newsml:reuters.com:*:nPnV1twZa
Further company coverage: CTIC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CTI Biopharma
See all newsBrief: CTI Biopharma Cancels 2023 Annual Meeting Of Stockholders
U.S. RESEARCH ROUNDUP-Albemarle, Ellington Financial, Savara
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
U.S. STOCKS ON THE MOVE-First Citizens BancShares, Sarepta, Celsius Holdings
U.S. STOCKS ON THE MOVE-Taboola, US banks, Copper miners